Novome Biotechnologies

Novome Biotechnologies is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics known as Genetically Engineered Microbial Medicines (GEMMs). The Company’s lead preclinical program in hyperoxaluria is focused on the development of a live biotherapeutic product that degrades oxalate to prevent the formation of kidney stones. Additional programs are being pursued in a range of indications that leverage the Company’s proprietary synthetic biology platform and expertise in the gut microbiome.